Germany · Delayed Price · Currency is EUR Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of EUR 6.95 billion. The enterprise value is 7.28 billion.
| Market Cap | 6.95B |
| Enterprise Value | 7.28B |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 122.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.00% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 116.93% |
| Float | 121.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 93.46 |
| PB Ratio | -15.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.36 |
| EV / Sales | 97.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.84 |
Financial Position
The company has a current ratio of 6.88
| Current Ratio | 6.88 |
| Quick Ratio | 6.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.98 |
| Interest Coverage | -5.96 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.93% |
| Return on Invested Capital (ROIC) | -41.55% |
| Return on Capital Employed (ROCE) | -44.26% |
| Revenue Per Employee | 149,257 |
| Profits Per Employee | -1.29M |
| Employee Count | 498 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.39% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +19.39% |
| 50-Day Moving Average | 51.52 |
| 200-Day Moving Average | 38.21 |
| Relative Strength Index (RSI) | 65.03 |
| Average Volume (20 Days) | 27 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.23 |
Income Statement
In the last 12 months, Cytokinetics had revenue of EUR 74.33 million and -640.88 million in losses. Loss per share was -5.38.
| Revenue | 74.33M |
| Gross Profit | -271.07M |
| Operating Income | -488.31M |
| Pretax Income | -640.88M |
| Net Income | -640.88M |
| EBITDA | -480.09M |
| EBIT | -488.31M |
| Loss Per Share | -5.38 |
Balance Sheet
The company has 820.37 million in cash and 1.15 billion in debt, giving a net cash position of -330.45 million.
| Cash & Cash Equivalents | 820.37M |
| Total Debt | 1.15B |
| Net Cash | -330.45M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -444.15M |
| Book Value Per Share | -3.63 |
| Working Capital | 711.85M |
Cash Flow
In the last 12 months, operating cash flow was -368.98 million and capital expenditures -17.43 million, giving a free cash flow of -386.42 million.
| Operating Cash Flow | -368.98M |
| Capital Expenditures | -17.43M |
| Free Cash Flow | -386.42M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -656.95% |
| Pretax Margin | -862.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.00% |
| Shareholder Yield | -11.00% |
| Earnings Yield | -9.23% |
| FCF Yield | -5.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 0.1666666667.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1666666667 |
Scores
Cytokinetics has an Altman Z-Score of -2.2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.2 |
| Piotroski F-Score | 3 |